Valuation: AbbVie Inc.

Market Cap 521B 473B 437B 394B 743B 49,171B 769B 5,251B 2,082B 26,266B 1,957B 1,916B 83,377B P/E 2026 *
37.6x
P/E 2027 * 27.7x
Enterprise Value 585B 530B 490B 442B 834B 55,148B 863B 5,889B 2,335B 29,459B 2,195B 2,148B 93,512B EV / Sales 2026 *
8.63x
EV / Sales 2027 * 7.79x
Free-Float
95.7%
Yield 2026 *
2.34%
Yield 2027 * 2.46%
1 day+0.20%
1 week+1.28%
Current month+0.05%
1 month+4.07%
3 months+18.27%
6 months+39.98%
Current year+29.12%
1 week 289.59
Extreme 289.59
300.42
1 month 278.01
Extreme 278.01
302.93
Current year 190.75
Extreme 190.75
302.93
1 year 190.75
Extreme 190.75
302.93
3 years 137.05
Extreme 137.05
302.93
5 years 115.01
Extreme 115.01
302.93
10 years 58.6
Extreme 58.6
302.93
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Date Insider Type Main position Quantity % Market Cap. Importance
30/09/26 Free

Director

59 0.0000%
30/09/26 Free

Director

129 0.0000%
14/08/26 Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+1.28%+26.97%+113.70% 521B
+1.26%+6.61%+40.79%+136.32% 1,286B
+0.79%+3.45%+45.84%+93.52% 688B
-0.44%+3.69%+41.45%+68.91% 386B
+0.55%+0.70%+59.02%+44.62% 364B
-0.12%+0.74%+28.39%+58.54% 302B
+0.37%+0.37%+3.33%+37.27% 287B
-0.30%+1.14%+38.29%+72.46% 252B
+0.08%+0.71%+34.44%+124.95% 208B
+0.98%+3.34%-10.48%-59.22% 181B
Average +0.34%+2.20%+30.80%+69.11% 448B
Weighted average by Cap. +0.56%+3.26%+35.75%+90.19%

Financials

2026 *2027 *
Net sales 67.8B 61.44B 56.83B 51.27B 96.62B 6,393B 100B 683B 271B 3,415B 254B 249B 10,839B 73.94B 67.01B 61.98B 55.92B 105B 6,972B 109B 745B 295B 3,724B 277B 272B 11,822B
Net income 14.35B 13B 12.03B 10.85B 20.45B 1,353B 21.17B 144B 57.29B 723B 53.85B 52.71B 2,294B 19.31B 17.5B 16.19B 14.61B 27.53B 1,821B 28.5B 194B 77.11B 973B 72.48B 70.94B 3,088B
Net Debt 63.39B 57.44B 53.13B 47.94B 90.34B 5,977B 93.53B 638B 253B 3,193B 238B 233B 10,135B 54.48B 49.37B 45.67B 41.2B 77.65B 5,137B 80.38B 549B 218B 2,744B 204B 200B 8,710B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
13/11/26 $295.03 +0.20% 3,262,103
12/11/26 $294.45 -0.18% 4,826,816
11/11/26 $294.98 +0.37% 3,262,250
10/11/26 $293.89 +0.20% 3,520,637
09/11/26 $293.30 +0.68% 5,867,056
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
MarketScreener Ratings - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
295.03USD
Average target price
311.81USD
Spread / Average Target
+5.69%
  1. Stock Market
  2. Stocks
  3. ABBV Stock